These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34864255)

  • 1. The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study.
    Post GS; Lustgarten J
    Top Companion Anim Med; 2022; 46():100616. PubMed ID: 34864255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An un-commissioned randomized, placebo-controlled double-blind study to test the effect of deep sea fish oil as a pain reliever for dogs suffering from canine OA.
    Hielm-Björkman A; Roine J; Elo K; Lappalainen A; Junnila J; Laitinen-Vapaavuori O
    BMC Vet Res; 2012 Sep; 8():157. PubMed ID: 22950577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a survey instrument to assess health-related quality of life in small animal cancer patients treated with chemotherapy.
    Iliopoulou MA; Kitchell BE; Yuzbasiyan-Gurkan V
    J Am Vet Med Assoc; 2013 Jun; 242(12):1679-87. PubMed ID: 23725431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression.
    Chen LM; Liu PY; Chen YA; Tseng HY; Shen PC; Hwang PA; Hsu HL
    Sci Rep; 2017 Sep; 7(1):11864. PubMed ID: 28928376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial.
    Yeh CW; Shih CJ; Liu TC; Chiou YL
    Sci Rep; 2022 Oct; 12(1):18150. PubMed ID: 36307493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quality of life and life expectancy of dogs undergoing chemotherapy for malignant lymphoma. An owner survey].
    Bergmann M; Sauter-Louis C; Hirschberger J
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2011; 39(4):229-36. PubMed ID: 22143660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway.
    Chen CH; Sue YM; Cheng CY; Chen YC; Liu CT; Hsu YH; Hwang PA; Huang NJ; Chen TH
    Sci Rep; 2017 Jan; 7():40183. PubMed ID: 28098144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients.
    Takahashi H; Kawaguchi M; Kitamura K; Narumiya S; Kawamura M; Tengan I; Nishimoto S; Hanamure Y; Majima Y; Tsubura S; Teruya K; Shirahata S
    Integr Cancer Ther; 2018 Jun; 17(2):282-291. PubMed ID: 28627320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double-blinded, placebo-controlled clinical trial.
    Yağci BB; Ural K; Ocal N; Haydardedeoğlu AE
    Vet Dermatol; 2008 Aug; 19(4):194-8. PubMed ID: 18494759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of accelerometry to investigate physical activity in dogs receiving chemotherapy.
    Helm J; McBrearty A; Fontaine S; Morrison R; Yam P
    J Small Anim Pract; 2016 Nov; 57(11):600-609. PubMed ID: 27709617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-tumor activity of brown seaweed oligo-fucoidan via lncRNA expression modulation in HepG2 cells.
    Yan MD; Lin HY; Hwang PA
    Cytotechnology; 2019 Feb; 71(1):363-374. PubMed ID: 30632031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study.
    Marsella R; Nicklin CF; Saglio S; Lopez J
    Vet Dermatol; 2004 Oct; 15(5):294-303. PubMed ID: 15500481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the clinical efficacy of 0.2% topical stannous fluoride for the treatment of canine superficial pyoderma: a prospective, randomized, double-blinded, placebo-controlled trial.
    Seltzer JD; Flynn-Lurie AK; Marsella R; Brennan MM
    Vet Dermatol; 2010 Jun; 21(3):249-58. PubMed ID: 20230586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligo-Fucoidan Prevents M2 Macrophage Differentiation and HCT116 Tumor Progression.
    Chen LM; Tseng HY; Chen YA; Al Haq AT; Hwang PA; Hsu HL
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32059469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomically Revealed Oligo-Fucoidan Enhances the Immune System and Protects Hepatocytes via the ASGPR/STAT3/HNF4A Axis.
    Cheng CC; Yang WY; Hsiao MC; Lin KH; Lee HW; Yuh CH
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32545625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a terbinafine-florfenicol-betamethasone acetate otic gel on the quality of life of dogs with acute otitis externa and their owners.
    Noli C; Sartori R; Cena T
    Vet Dermatol; 2017 Aug; 28(4):386-e90. PubMed ID: 28295766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined protective effects of oligo-fucoidan, fucoxanthin, and L-carnitine on the kidneys of chronic kidney disease mice.
    Chen YC; Cheng CY; Liu CT; Sue YM; Chen TH; Hsu YH; Huang NJ; Chen CH
    Eur J Pharmacol; 2021 Feb; 892():173708. PubMed ID: 33152336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: a double-blind, placebo-controlled study.
    Chretin JD; Rassnick KM; Shaw NA; Hahn KA; Ogilvie GK; Kristal O; Northrup NC; Moore AS
    J Vet Intern Med; 2007; 21(1):141-8. PubMed ID: 17338162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Questionnaire-based assessment of owner concerns and doctor responsiveness: 107 canine chemotherapy patients.
    Hamilton MJ; Sarcornrattana O; Illiopoulou M; Xie Y; Kitchell B
    J Small Anim Pract; 2012 Nov; 53(11):627-33. PubMed ID: 22957892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.
    Alexea O; Bacarea V; Piqué N
    United European Gastroenterol J; 2016 Jun; 4(3):455-65. PubMed ID: 27403313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.